Skip to main content
. Author manuscript; available in PMC: 2012 Nov 6.
Published in final edited form as: Aliment Pharmacol Ther. 2010 Nov 2;33(1):127–137. doi: 10.1111/j.1365-2036.2010.04503.x

Table 3.

Morphometric collagen content at each biopsy by stratum of silymarin use

Baseline Biopsy Biopsy 1 (year 1.5) Biopsy 2 (year 3.5) Overall P-value across repeated biopsies

Silymarin use Mean (SD) No. P-value relative to never users Mean (SD) No. P-value relative to never users Mean (SD) No. P-value relative to never users
All patients
Never (No.=701) 0.061 (0.061) 361 Referent group 0.088 (0.079) 358 Referent group 0.090 (0.085) 271 Referent group Referent group
Former (No.=178) 0.062 (0.058) 113 0.82 0.089 (0.092) 100 0.81 0.077 (0.087) 69 0.15 0.93
Current (No.=170) 0.054 (0.056) 84 0.17 0.068 (0.053) 92 0.10 0.071 (0.069) 69 0.061 0.037

Fibrosis at baseline
Never (No.=421) 0.039 (0.036) 231 Referent group 0.070 (0.064) 239 Referent group 0.069 (0.065) 182 Referent group Referent group
Former (No.=104) 0.037 (0.028) 71 0.95 0.070 (0.088) 64 0.38 0.064 (0.072) 48 0.41 0.53
Current (No.=96) 0.031 (0.027) 46 0.15 0.063 (0.057) 58 0.25 0.043 (0.036) 42 0.018 0.034

Cirrhosis at baseline
Never (No.=280) 0.101 (0.075) 130 Referent group 0.124 (0.092) 119 Referent group 0.134 (0.103) 89 Referent group Referent group
Former (No.=74) 0.105 (0.070) 42 0.60 0.122 (0.089) 36 0.97 0.107 (0.110) 21 0.14 0.98
Current (No.=74) 0.081 (0.069) 38 0.052 0.077 (0.045) 34 0.023 0.115 (0.086) 27 0.48 0.011

Abbreviations: SD, standard deviation; No, number.

Assessment of morphometric collagen content was limited to biopsies with at least 10 mm2 of tissue, including 558 biopsies at baseline, 550 biopsies at year 1.5, and 409 biopsies at year 3.5.

Mann-Whitney test for the difference between mean collagen content in former or current silymarin users relative to never users.

P-value for the overall effect of silymarin use on morphometric collagen content across repeated biopsies was assessed by repeated-measures analysis of variance assuming an autoregressive covariance structure. Time (baseline, biopsy 1, and biopsy 2) and silymarin use were included in the models as fixed effects.